CClinicalTrials.gg
RecruitingNCT05890092VdiNUpdated Jun 6, 2023

Vulvar Disease in Nigeria Observational Study

An observational study in Vulvar Diseases, Vulvar Atrophy and Dermatoses, sponsored by KDRS ltd. Recruiting at 1 site in United Kingdom. Open to female participants aged 10 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-06-06.

Sponsored by KDRS ltd · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
1,000
Ages
10 Years to 90 Years
Sex
Female
01

Study summary

Vulvar disease in Nigeria A look at awareness within patients and health practitioners, self-reported and actual prevalence within communities in Nigeria

02

Conditions studied

  • Vulvar Diseases
  • Vulvar Atrophy
  • Dermatoses

Browse trials for

03

Who can participate

Ages eligible
10 Years to 90 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

All afab, willing to participate in the study.

Inclusion criteria

  • biological females - afab

Exclusion criteria

Exclusion Criteria:

  • none-afab
04

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Interventions

  • OtherObservation

    Observing for disease prevalence - actual and self-reported

05

What researchers measure

Primary outcomes

  1. Prevalence of Vulvar disease

    Awareness of Vulvar disease (descriptor)

    Time frame: 1-12 months

06

Study locations

1 of 1 sites recruiting
  • Kdrs
    London, Rm166el, United Kingdom
    • Lead Research officer · Contact · towales1@gmail.com · 00447984470726
    • Dr Adedipe, MRCOG · Principal investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05890092
Lead sponsor
KDRS ltd
Responsible party
Sponsor
First posted
Jun 6, 2023
Start date
May 3, 2023
Primary completion
May 2, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Jun 6, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion